Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Grant Blauvelt

Nurse Practitioner, Family Fort Wayne, IN Nurse Practitioner

NPI 1477122711 CMS profile 10458827

7900 W Jefferson Blvd Ste 201, Fort Wayne, IN 46804

Open in the dashboard

General payments

$28,010

763 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Grant Blauvelt of Fort Wayne, IN is reported in the CMS Open Payments database as having received $28,010 across 763 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,993 193
2024 General $9,331 176
2023 General $3,266 185
2022 General $2,639 150
2021 General $1,781 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Grant Blauvelt
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Grant Blauvelt were reported at $10,993. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Grant Blauvelt Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,781 $124 $35–$379 $132
2022 $2,639 $141 $44–$430 $149
2023 $3,266 $154 $49–$476 $160
2024 $9,331 $165 $51–$504 $164
2025 $10,993 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Dexcom, Inc. $12,463 57 payments
  2. Enterra Medical, Inc. $1,481 5 payments
  3. Novo Nordisk Inc $1,439 92 payments
  4. Corcept Therapeutics $1,360 61 payments
  5. Lilly USA, LLC $1,249 81 payments
  6. Alexion Pharmaceuticals, Inc. $1,064 21 payments
  7. Tandem Diabetes Care, Inc. $1,012 54 payments
  8. Sanofi-Aventis U.S. LLC $674 28 payments
  9. AstraZeneca Pharmaceuticals LP $630 29 payments
  10. Medtronic, Inc. $549 32 payments
  11. Other $6,089 303 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,823 728 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $9,525 8 payments
  3. Travel and Lodging $2,969 19 payments
  4. Consulting Fee $525 1 payment
  5. Education $168 7 payments
Products named General payments · program years 2021–2025
  1. DEXCOM G7 GSS (161) $11,902 31 payments
  2. DEXCOM STELO GLUCOSE BIOSENSOR $6,384 17 payments
  3. Korlym $1,360 61 payments
  4. STRENSIQ $943 20 payments
  5. RYBELSUS $920 70 payments
  6. t:slim X2 Insulin Pump with Control-IQ $897 48 payments
  7. Ozempic $867 73 payments
  8. MOUNJARO $750 45 payments
  9. FARXIGA $630 29 payments
  10. Dexcom G6 Transmitter $561 26 payments
  11. Other $10,325 552 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

2,437

Median for Nurse Practitioner: 389

Drug cost

$1,548,616

Median for Nurse Practitioner: $21,885

Branded share of claims

65.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 279 $436,507
Jardiance Empagliflozin Brand 255 $306,629
Mounjaro Tirzepatide Brand 177 $282,193
Trulicity Dulaglutide Brand 43 $72,704
Farxiga Dapagliflozin Propanediol Brand 52 $55,387
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 40 $51,518
Humalog Kwikpen U-100 Insulin Lispro Brand 71 $44,516
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 21 $37,496
Xultophy 100-3.6 Insulin Degludec/Liraglutide Brand 18 $35,004
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 147 $32,630

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$26,007

Medicare's payments for the services billed

Medicare patients

129

Average age 72

Services billed

767

70 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 71%
Chronic kidney disease 49%
Ischemic heart disease 41%
Arthritis 41%
Depression 33%
Atrial fibrillation 25%
Heart failure 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $634
$634 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $198
  • Lilly USA, LLC $73
$271 255 —
STRENSIQ
  • Alexion Pharmaceuticals, Inc. $131
$131 — —
MOUNJARO
  • Lilly USA, LLC $125
$125 177 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $118
$118 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

763 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record